These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 20558909)
1. Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients. Nakano N; Ishimitsu T; Takahashi T; Inada H; Okamura A; Ohba S; Matsuoka H Int Heart J; 2010 May; 51(3):188-92. PubMed ID: 20558909 [TBL] [Abstract][Full Text] [Related]
2. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ohta S; Yoshii M; Minami J; Ono H; Numabe A; Matsuoka H Hypertens Res; 2007 Jul; 30(7):621-6. PubMed ID: 17785930 [TBL] [Abstract][Full Text] [Related]
3. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. Sasaki H; Saiki A; Endo K; Ban N; Yamaguchi T; Kawana H; Nagayama D; Ohhira M; Oyama T; Miyashita Y; Shirai K J Atheroscler Thromb; 2009 Oct; 16(5):568-75. PubMed ID: 19749494 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension. Tanaka T; Tsutamoto T; Sakai H; Fujii M; Yamamoto T; Horie M Hypertens Res; 2007 Aug; 30(8):691-7. PubMed ID: 17917316 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. Imagawa K; Okayama S; Takaoka M; Kawata H; Naya N; Nakajima T; Horii M; Uemura S; Saito Y J Cardiovasc Pharmacol; 2006 Jan; 47(1):133-8. PubMed ID: 16424797 [TBL] [Abstract][Full Text] [Related]
7. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension. Tsutamoto T; Tanaka T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M Hypertens Res; 2009 Aug; 32(8):670-4. PubMed ID: 19498438 [TBL] [Abstract][Full Text] [Related]
8. L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension. Ogura C; Ono K; Miyamoto S; Ikai A; Mitani S; Sugimoto N; Tanaka S; Fujita M Blood Press; 2012 Dec; 21(6):367-71. PubMed ID: 22747420 [TBL] [Abstract][Full Text] [Related]
9. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats. Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815 [TBL] [Abstract][Full Text] [Related]
10. On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone. Konoshita T; Kaeriyama S; Urabe M; Nakaya T; Yamada M; Ichikawa M; Yamamoto K; Sato S; Imagawa M; Fujii M; Makino Y; Zenimaru Y; Wakahara S; Suzuki J; Ishizuka T; Nakamura H; Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27515419 [TBL] [Abstract][Full Text] [Related]
11. Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels. Tanaka H; Shigenobu K Cardiovasc Drug Rev; 2002; 20(1):81-92. PubMed ID: 12070536 [TBL] [Abstract][Full Text] [Related]
12. A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker. Konoshita T; Makino Y; Kimura T; Fujii M; Wakahara S; Arakawa K; Inoki I; Nakamura H; Miyamori I; J Hypertens; 2010 Oct; 28(10):2156-60. PubMed ID: 20625317 [TBL] [Abstract][Full Text] [Related]
13. The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium. Tanaka H; Komikado C; Shimada H; Takeda K; Namekata I; Kawanishi T; Shigenobu K J Pharmacol Sci; 2004 Dec; 96(4):499-501. PubMed ID: 15599089 [TBL] [Abstract][Full Text] [Related]
14. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm. Konda T; Enomoto A; Aritomi S; Niinuma K; Koganei H; Ogawa T; Nitta K Am J Nephrol; 2009; 30(2):155-61. PubMed ID: 19325231 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. Takai S; Jin D; Sakonjo H; Miyazaki M Hypertens Res; 2010 Sep; 33(9):953-9. PubMed ID: 20520612 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats. Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553 [TBL] [Abstract][Full Text] [Related]
17. Effects of efonidipine hydrochloride on heart rate and circulatory changes due to stress. Morimoto S; Jo F; Maki K; Iwasaka T Clin Exp Hypertens; 2009 Feb; 31(1):83-91. PubMed ID: 19172462 [TBL] [Abstract][Full Text] [Related]
18. Efonidipine, a Ca(2+)-channel blocker, enhances the production of dehydroepiandrosterone sulfate in NCI-H295R human adrenocortical carcinoma cells. Ikeda K; Saito T; Tojo K Tohoku J Exp Med; 2011 Aug; 224(4):263-71. PubMed ID: 21757861 [TBL] [Abstract][Full Text] [Related]
19. Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. Perez-Reyes E; Van Deusen AL; Vitko I J Pharmacol Exp Ther; 2009 Feb; 328(2):621-7. PubMed ID: 18974361 [TBL] [Abstract][Full Text] [Related]
20. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. Abe M; Maruyama N; Suzuki H; Inoshita A; Yoshida Y; Okada K; Soma M Heart Vessels; 2013 Jul; 28(4):480-9. PubMed ID: 22914905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]